We are live on ! Find out more
GILD icon

Gilead Sciences

1,264 hedge funds and large institutions have $115B invested in Gilead Sciences in 2014 Q2 according to their latest regulatory filings, with 164 funds opening new positions, 527 increasing their positions, 461 reducing their positions, and 82 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 164 | Existing positions closed: 82

46% more funds holding in top 10

Funds holding in top 10: 112164 (+52)

14% more repeat investments, than reductions

Existing positions increased: 527 | Existing positions reduced: 461

6% more funds holding

Funds holding: 1,1881,264 (+76)

1% less capital invested

Capital invested by funds: $116B → $115B (-$753M)

3.24% less ownership

Funds ownership: 95.31%92.07% (-3.2%)

24% less call options, than puts

Call options by funds: $2B | Put options by funds: $2.62B

Holders
1,264
Holders Change
+76
Holders Change %
+6.4%
% of All Funds
36.21%
Holding in Top 10
164
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+46.43%
% of All Funds
4.7%
New
164
Increased
527
Reduced
461
Closed
82
Calls
$2B
Puts
$2.62B
Net Calls
-$615M
Net Calls Change
+$553M

GILD Hedge Fund Activity: Q2 2014 in Review

1,264 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2014, worth a combined $115B — down 0.65% from $116B a quarter earlier.

Buyers outnumbered sellers: 164 funds opened new GILD positions and 82 closed out — a net gain of 82 holders — while 527 added to existing stakes and 461 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.16B. The largest seller was BNP Paribas Financial Markets, cutting an estimated $3.85B.

  • 1,264 institutional investors held Gilead Sciences (GILD) as of Q2 2014, up from 1,188 in Q1 2014.
  • Funds reported $115B of Gilead Sciences stock for Q2 2014, down 0.65% quarter-over-quarter.
  • 164 funds opened new Gilead Sciences positions in Q2 2014 and 82 closed out, a net change of +82 holders.
  • The largest Gilead Sciences buyer in Q2 2014 was Capital Research Global Investors, an estimated $1.16B added.
  • The largest Gilead Sciences seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $3.85B sold.

Based on aggregated 13F filings for Q2 2014.